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2. Abstract: 38 
Objective: Hyperglycemia during pregnancy increases risk of adverse health outcomes in mother 39 
and child, but the genetic aetiology is scarcely studied. Our aims were to 1) assess the overlapping 40 
genetic aetiology between the pregnant and non-pregnant population and 2) assess the importance 41 
of genome-wide polygenic contributions to glucose traits during pregnancy, by exploring whether 42 
genetic risk scores (GRS) for fasting glucose (FG), 2-hour glucose (2hG), type 2 diabetes (T2D) 43 
and body mass index (BMI) in non-pregnant individuals were associated with glucose measures 44 
in pregnant women.  45 
Methods: We genotyped 529 Norwegian pregnant women and constructed GRS from known 46 
genome-wide significant variants and SNPs weakly associated (p>5x10-8) with FG, 2hG, BMI and 47 
T2D from external genome-wide association studies (GWAS) and examined the association 48 
between these scores and glucose measures at gestational week 14-16 and 30-32. We also 49 
performed GWAS of FG, 2hG and shape information from the glucose curve during an oral 50 
glucose tolerance test (OGTT). 51 
Results: GRSFG explained similar variance during pregnancy as in the non-pregnant population 52 
(~5%). GRSBMI and GRST2D explained up to 1.3% of the variation in the glucose traits in 53 
pregnancy. If we included variants more weakly associated with these traits, GRS2hG and GRST2D 54 
explained up to 2.4% of the variation in the glucose traits in pregnancy, highlighting the 55 
importance of polygenic contributions. 56 
Conclusions: Our results suggest overlap in the genetic aetiology of FG in pregnant and non-57 
pregnant individuals. This was less apparent with 2hG, suggesting potential differences in 58 
postprandial glucose metabolism inside and outside of pregnancy.    59 
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3. Introduction: 60 
Metabolic adaption during pregnancy is important to ensure growth and development of the fetus 61 
and to guarantee that the mothers’ elevated energy needs during the pregnancy are met1. Glucose 62 
is the major energy source for the fetus which freely crosses the placenta. Two major changes in 63 
glucose metabolism take place during pregnancy. First, fasting glucose levels decrease during 64 
early pregnancy, mainly due to an increase in plasma volume2. Secondly, pregnancy has a 65 
diabetogenic effect on the mother, with increased insulin resistance usually commencing after the 66 
first trimester. Regardless of the changes in maternal glucose metabolism, and the increase in 67 
insulin resistance, maternal fasting blood glucose values normally remain relatively stable 68 
throughout pregnancy1. This is largely because of fetal glucose utilization, although postprandial 69 
glucose levels tend to increase3. However, if the maternal beta cells are not able to compensate for 70 
insulin resistance by producing more insulin, the mother runs the risk of hyperglycemia.  71 
The large, multicenter, Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study showed 72 
a clear and graded relationship between plasma glucose values during pregnancy and increased 73 
disease burden in the mother and offspring4, 5. Hence, hyperglycemia in pregnancy — even without 74 
gestational diabetes (GDM) diagnosis — is associated with increased risk of adverse health 75 
outcomes in both mother and child6, 7. Additionally, it has been estimated that around 50% of the 76 
women diagnosed with GDM will develop type 2 diabetes (T2D) within 5-10 years, although the 77 
exact risk varies with the criteria used and the follow-up time8, 9. GDM and T2D appear to share 78 
both genetic and non-genetic risk factors — such as high body mass index (BMI) — and the 79 
overlapping susceptibility may partly explain the increased risk of T2D for women with previous 80 
GDM10, 11. 81 
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Glucose levels in pregnancy are usually measured in the fasting state or (one and) two hours after 82 
an oral glucose tolerance test (OGTT). Commonly, single measurements — such as fasting glucose 83 
levels (FG) and 2 hour post OGTT glucose levels (2hG) — are used to diagnose GDM. However, 84 
different patterns of the glucose levels during an OGTT can yield the same single measurements, 85 
and thus the shape of the glucose curves may provide important additional information. Functional 86 
data analysis (FDA)12 of OGTT glucose curves has previously been used to extract shape 87 
information not apparent in commonly used simple measures. Briefly, the most important curve 88 
shape characteristic, interpreted as the general glucose level during an OGTT, was positively 89 
associated with all OGTT measurements and closely related to the area under the OGTT curve 90 
(AUC). The second most important shape characteristic described to what extent the women had 91 
a longer than average time to peak and a prolonged time to return to fasting glucose levels. The 92 
latter curve shape information was found to  successfully discriminate between women who did 93 
and did not develop GDM later in pregnancy13, indicating that the glucose curve shape might hold 94 
valuable information of clinical relevance.  95 
Genetic factors are thought to contribute to the increase in blood glucose concentrations during 96 
pregnancy. However, whilst more than 100 SNPs have been robustly associated with glycemic 97 
traits, hyperglycemia and T2D in the non-pregnant population14, 15, there are only a few published 98 
studies on such associations in pregnant women 10, 11, 16, 17 and it is still not known how well SNPs 99 
robustly associated with glucose levels outside of pregnancy14 are associated in pregnancy. 100 
In the present study we genotyped up to 529 pregnant women from the Norwegian STORK cohort 101 
with glucose phenotypes measured both in the first and third trimester of pregnancy18. The placenta 102 
is assumed to play an important role in the metabolic changes during pregnancy and the two time 103 
points for the OGTTs during pregnancy were chosen to reflect the time before the placenta is well 104 
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established (around gestational week 20), and the time after the placenta is well established and 105 
the fetus is gaining weight, in the third trimester. We constructed genetic risk scores (GRS) of 106 
known SNPs for FG, 2hG, BMI and T2D and examined the association with the glucose variables 107 
at the two time-points during pregnancy, to study the effect of GRSs on the changes in glucose 108 
metabolism during pregnancy. In addition to the longitudinal data, the present study introduces the 109 
novel approach of combining genetic risk scores with glucose curve shape information in the 110 
analyses. We also present genome-wide association studies (GWAS) for FG, 2hG and shape of the 111 
glucose curve during an OGTT. Our aims were to examine the genetic determinants of glucose 112 
metabolism during pregnancy, ascertain whether genetic variants robustly associated with glucose 113 
metabolism in the non-pregnant population were also associated with the same variables in early 114 
and late pregnancy, and to see whether known genetic variants associated with T2D and BMI were 115 
related to glucose variables during pregnancy.    116 
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4. Subjects and methods: 117 
4.1. The STORK study 118 
The STORK study is a prospective cohort of 1031 healthy pregnant women of Scandinavian 119 
ancestry who registered for obstetric care at the Oslo University Hospital Rikshospitalet from 2001 120 
to 200818. Exclusion criteria were multiple pregnancy, known history of type 1 or type 2 diabetes 121 
mellitus, and severe chronic diseases (pulmonary, cardiac, gastrointestinal, or renal). Results of a 122 
75 g OGTT, age, height and weight were recorded at inclusion at gestational weeks (GW) 14-16. 123 
The OGTT was repeated at GW 30-32. This paper includes up to n = 529 individuals with genotype 124 
and repeated clinical and laboratory examinations (Figure 1). We did not exclude women from the 125 
analysis on the basis of GDM diagnosis in pregnancy. The study was approved by the Regional 126 
Committee for Medical Research Ethics, Southern Norway, Oslo, Norway (reference number S-127 
2014/224- 0119a & S-07392a), and performed according to the Declaration of Helsinki. All 128 
participating women provided written informed consent. 129 
4.2. Measurements of glucose 130 
All OGTTs were performed after an overnight fast. Blood samples were taken every 30 minutes 131 
for 2 hours, for a total of five OGTT measurements per woman. Briefly, venous blood was drawn 132 
in gel tubes, allowed to clot for 30 min, and thereafter centrifuged for 10 min at 1800 g. Serum was 133 
separated and stored at −80 °C. Glucose was measured from frozen serum samples as previously 134 
reported19 from antenatal visits at GW 14-16 and GW 30-32, with the hexokinase method at an 135 
accredited clinical chemistry laboratory at Oslo University Hospital, Rikshospitalet (Cobas 6000  136 
from Roche, Rotkreuz, Switzerland).  137 
4.3. Extracting curve shape information from OGTT glucose curves  138 
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Extraction of curve shape information from OGTT data at GW 14-16  has previously been 139 
described in detail13. In the present study, OGTT data from GW 14-16 and 30-32 were analyzed 140 
separately. Seven women included in the study were diagnosed with GDM (WHO99 criteria20) 141 
after GW 14-16, however they were only treated with dietary advice and they were therefore 142 
included in the analysis at GW 30-32. Briefly, the five OGTT measurements from the 497 women 143 
in the study sample with genetic data and complete OGTT data at GW 14-16 were converted into 144 
497 continuous, smooth curves (SF1-A). The same procedure was used for the 506 women with 145 
genetic data and complete OGTT data at GW 30-32 (SF1-B). A common smoothing parameter 146 
was used in both smoothing procedures21. These 497 and 506 individually fitted curves formed the 147 
basis for two separate functional principal component analyses (FPCAs), in which curve shape 148 
information was extracted.  149 
In a FPCA, curve shape information is decomposed into a small set (e.g. two) of common principal 150 
component (PC) curves, and a corresponding set of individual PC scores, one score per PC per 151 
woman. As shown previously13, the PC curves can be given physiological interpretations 152 
according to the temporal variation (shape) they exhibit. A woman’s set of individual PC scores 153 
reflects how her individual glucose curve shape corresponds to the general temporal feature 154 
expressed by the PC curves. Hence, the PC score values from GW 14-16 and 30-32 were used as 155 
outcome variables for the shape information inherent in the OGTT glucose curves. FDA (curve 156 
fitting and FPCA) was performed using the fda package in R (https://cran.r-project.org/).  157 
4.4. DNA extraction 158 
At weeks 22-24 and 36-38 peripheral blood mononuclear cells (PBMCs) were isolated from 159 
venous blood using BD Vacutainer CPT Tubes (BD, NJ, USA), centrifuged immediately at 2500 160 
rpm for 25 min, buffycoat separated and transferred carefully to nunc-tubes and stored at −80°C 161 
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until extraction. DNA was extracted using MagNA Pure Isolation Kit and Instrument (Roche Life 162 
Science, Penzberg, Germany) at weeks 22-24 and with MagMAX Isolation Kit and Instrument 163 
(Applied Biosystems, Carlsbad, CA, USA) at weeks 36-38, due to changes in instrumentation at 164 
the laboratory over the years. To include as many participants as possible, DNA was also extracted 165 
from 291 full blood venous samples stored at −70°C  containing Ethylenediaminetetraacetic acid 166 
(EDTA) from the follow-up study19, using a salting out procedure22 (Miller SA, 1215). Where 167 
several DNA samples were available only one was used for genotyping.  168 
4.5. Genotyping and Genome-wide association analysis 169 
DNA samples were genotyped on the Illumina Infinium CoreExome chip using Illumina iScan by 170 
the Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden. 171 
Of the 1031 individuals who provided blood samples, 455 had low quality or low concentration of 172 
DNA or withdrew consent (n = 3) and could not be analyzed further. Of the 573 remaining samples, 173 
those with low call rate (i.e. < 95%, n=0), extreme heterozygosity (> |mean± (3xSD)|, n=0), 174 
mismatched gender (n=2), cryptic relatedness (i.e. one individual (chosen at random) from each 175 
related pair, defined as genome-wide IBD > 0.185 (n=6) was removed from analysis), or of 176 
outlying ancestry (defined by ancestry informative principal component analysis based on the 177 
variance-standardized relationship matrix generated in PLINK 1.9 software package23 178 
(https://www.cog-genomics.org/plink/1.9/), n=36) were excluded from analyses (the ancestry of 179 
samples is illustrated  in SF2 which plots principal coordinates obtained via multidimensional 180 
scaling). This left 529 participants with useable SNP data. Variants with call rate <95% (14730 181 
SNPs), out of Hardy-Weinberg equilibrium (exact p<10-6, 66 SNPs) or with low minor allele 182 
frequency (MAF) <1% (254802 SNPs) were removed before imputation. Quality control was 183 
performed using the PLINK 1.9 software package23. After quality control, 281589 variants were 184 
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left for imputation. The GWAS scaffold was mapped to NCBI build 37 of the human genome, and 185 
imputation to the 1000G reference panel (Phase3- http://www.well.ox.ac.uk/~wrayner/tools/) for 186 
European ancestry was performed using IMPUTEv2.3.224. 84609303 SNPs were available after 187 
imputation. All SNPs with MAF < 0.02 and imputation quality < 0.4 were removed from analysis. 188 
A total of 8717487 SNPs were available for GW 14-16 and 8709903 SNPs were available for GW 189 
30-32.  190 
GWAS analysis of the traits FG, 2hG and curve shape variables (PC1 and PC2) was performed on 191 
the expected allele counts using linear regression assuming an additive genetic model in the 192 
software package SNPTEST25. The QQman R package26 was used for visualization. Test statistics 193 
with p-values ≤ 5x10-8 were considered genome-wide significant.  194 
4.6. Generating genetic risk scores  195 
In order to construct genetic risk scores (GRS), we used publicly available GWAS data for FG14 196 
(n=46186), 2hG14 (n=42,854), BMI27 (n=339,224) and T2D28 (n=26,676 T2D cases and 132,532 197 
controls). We constructed weighted GRS based on the published regression coefficients from the 198 
discovery meta-analysis of these papers using the PLINK 1.9 software package23. We constructed 199 
scores using known variants only (i.e. genome-wide significant SNPs from the above papers), and 200 
using nominally associated variants selected from across the genome meeting a particular p-value 201 
threshold (i.e. p < 5 x 10-7; p< 5 x 10-6; p< 5 x 10-5; p< 5 x 10-4; p< 0.005; p< 0.05;  p< 0.1; p< 0.2; 202 
p< 0.3; p< 0.4; p< 0.5; p< 0.6; p< 0.7; p< 0.8; p< 0.9 & all p-values) in order to capture polygenicity 203 
in these traits29, 30.  For the known risk scores, if the papers reported several SNPs at one locus, LD 204 
was checked and a set of independent (pairwise r2 < 0.2) SNPs with the lowest p values were 205 
selected to contribute to the scores. Details of the genome-wide significant variants used in 206 
construction of the known GRS can be found in Supplementary Tables ST1-4.  207 
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To evaluate the ability of GRS of known SNPs to explain variation in glycemic related traits in 208 
pregnancy, we fitted a multiple regression model that contained a term capturing the effect of the 209 
known variants. We also investigated whether polygenicity might help explain variation in our 210 
traits of interest. This was done by including an extra term that captured the effect of the GRS of 211 
nominally associated variants at the different p-value thresholds. In order to guard against the 212 
possibility of residual population stratification contaminating our results, we also included 213 
covariate terms for the first two ancestry informative principal components in the model. The 214 
variance explained by the GRS was quantified by reporting the difference in r-squared between 215 
the full regression model containing all effects and a nested sub-model containing only the effects 216 
of the ancestry informative principal components. Scores yielding p-values ≤ 0.05 in this 217 
comparison model were considered significant. To account for the 32 statistical tests (4 GRS x 8 218 
outcomes) we also evaluated our results against a Bonferroni corrected α level of 0.0016. All 219 
analyses were performed using RStudio Version 1.0.153. 220 
4.7. Power Calculations 221 
To estimate the power in our study we used the genetic power calculator31. We calculated the 222 
power for a GWAS assuming a two tailed type 1 error rate and an α = 5x10-8. We examined power 223 
to detect association at variants known to affect fasting glucose measures and power to detect 224 
association using GRS. Here we assumed a one tailed type 1 error rate of α = 0.05 given that we 225 
were making a specific directional hypothesis with regards to these known variants. Finally we 226 
estimated the power to detect variation explained by the known GRS assuming a one degree of 227 
freedom test with two tails with α = 0.05.   228 
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5. Results:  229 
5.1. Sample characteristics and glucose variables 230 
Characteristics of the study sample, and glucose measurements at GW 14-16 and 30-32 are shown 231 
in Table 1. Except for a small difference in age (p=0.02), (i.e. those with available genetic data 232 
were slightly older than those without), the clinical characteristics of women with genetic data 233 
available were not significantly different from those without genetic data (0.14≤p≤0.93). The 234 
individually fitted OGTT glucose curves at GW 14-16 and 30-32 are shown in SF1 A and B. 235 
At GW 14-16, results from the FPCA showed that the first two components describing the shape 236 
of the glucose curve (PC1 and PC2, SF1 C and D) explained 89% and 8% of the temporal variation 237 
between the fitted curves, respectively. Similarly, at GW 30-32, results from the FPCA showed 238 
that the first two PCs (PC1 and PC2, SF1 E and F) explained 86% and 10% of the temporal 239 
variation between the fitted curves, respectively. Since PC1 scores were highly correlated with 240 
area under the OGTT curve (r=0.999 (GW 14-16) and r=0.997 (GW 30-32)) the label “General 241 
glucose level” was chosen for this variable. PC2 scores, on the other hand, corresponded to time 242 
of the highest glucose level and the label “Timing of glucose curve peak” was therefore chosen for 243 
this variable. The PCs were labelled according to the physiological information they comprised, 244 
based on plots of how an individual curve differed from the mean curve if the corresponding PC 245 
scores are low or high (SF1 C and D)12, 13. Descriptive statistics for the corresponding PC scores 246 
are given in Table 1. It was noted that neither the mean curves, nor the PC curves at GW 14-16 247 
and 30-32 were identical (SF1 C and E, and D and F, respectively), and the PC scores from the 248 
two time points should therefore not be directly compared. 249 
5.2. Genetic risk scores 250 
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We found that the GRS for FG (GRSFG) explained a similar amount of variance in FG in pregnancy 251 
at both measurement occasions as in the MAGIC consortium data (Table 2, SF7). GRS2hG 252 
consisting of known variants did not explain 2hG variation during pregnancy well (Table 2). 253 
However, when we included nominally associated variants in construction of the GRS by relaxing 254 
the p-value threshold for the inclusion of SNPs in the risk score, we explained far larger 255 
proportions of the variance in 2hG during pregnancy, highlighting the importance of polygenic 256 
contributions to the trait (SF8). A similar trend was seen for GRST2D (Table 2), where known 257 
variants explained a small significant proportion of the variance in 2hG and PC1. This proportion 258 
increased with the inclusion of nominally associated SNPs from the T2D GWAS (SF9). GRSBMI 259 
explained some of the variance in FG, 2hG and PC1 (Table 2), and an increase in variance 260 
explained was also observed when the p-value threshold was lowered (SF10). PC2 was not 261 
significantly associated with any of the risk scores.  262 
We had between 85% and >99% power to detect association (assuming a two tailed α=0.05) for a 263 
GRS that explained the smallest and largest expected proportions of the trait variance (i.e. the GRS 264 
of known variants is expected to explain 1.7% of the variation in 2hG and 4.8% of the variance in 265 
FG according to the literature14). Thus, we are well powered to detect association between our 266 
GRS and glucose related traits in pregnancy (should the underlying genetic etiology of the traits 267 
be similar). 268 
3.3 Genome-wide association study 269 
The results from the GWAS analysis can be found in the Supplementary material and in SF3-4. 270 
Our main findings are shown in ST5. The results from the look-up of known SNPs are shown in 271 
ST1-4. However, our study had low power (<40%) to detect single loci that explained 5% of the 272 
phenotypic trait variance at genome-wide levels of significance (α=5x10-8) (power = 1% for a 273 
14 
 
  
variant explaining 2% of the variation). Since it would be very unusual for quantitative trait loci 274 
underlying complex traits to explain such large proportions of the phenotypic variance it follows 275 
that we must be cautious in interpreting the results. In the case of our look up of known glucose 276 
variants, we had 49% power to detect SNPs explaining 0.5% of the phenotypic variance, and 81% 277 
power to detect variants explaining 1.2% of the variation in the trait. Previously published GWAS 278 
indicate that most of the known loci contributing to glucose related traits do not explain such large 279 
proportions of the phenotypic variance in individuals in the non-pregnant population. Assuming 280 
the same in our sample of pregnant individuals suggests that we are also underpowered to detect 281 
specific known loci.  282 
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6. Discussion  283 
By analysing GRS of known and nominally associated variants, we found that SNPs robustly 284 
associated with glucose measurements in the non-pregnant population also explain significant 285 
proportions of the variance in the glucose measurements in a cohort of pregnant Norwegian women. 286 
Furthermore; we found that some single genetic variants associated with glucose metabolism in 287 
the non-pregnant population are also associated with the same measures during pregnancy - 288 
although the statistical power for these confirmatory analyses was low.  289 
GRSFG explained a similar percentage of variance in FG values during pregnancy as in non-290 
pregnant individuals14. These finding was consistent in early and late pregnancy and the 291 
associations were still significant after Bonferroni correction. GRSFG also explained a small, but 292 
significant percentage of the variation in 2hG and the general OGTT glucose level (PC1). Due to 293 
the strong association between GRSFG and both FG and 2hG, and our previous findings of high 294 
correlations between PC1 scores and all OGTT glucose measurements13, the observed effect on 295 
PC1 was expected. 296 
Surprisingly, no effects on the glucose phenotypes were found for GRS2hG. However, SNPs just 297 
beneath the genome-wide significance level (e.g. p-value threshold of <5x10-7) explained more of 298 
the variance in this trait. This might suggest that SNPs weakly associated with 2hG in the non-299 
pregnant population may be more important during pregnancy. Our findings highlight the 300 
importance of the polygenic contributions to the trait.  301 
The fact that GRSFG explained a similar percentage of variation in the trait both early and late in 302 
pregnancy compared to a non-pregnant population whereas GRS2hG explained a negligible (and 303 
not significant) proportion of the variation in 2hG and PC1 during pregnancy is interesting as we 304 
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know that FG values normally remain relatively stable throughout pregnancy1 but that the 305 
postprandial glucose levels tend to increase3. This leads us to speculate that the underlying genetic 306 
mechanisms for FG are similar in both pregnant and non-pregnant individuals, but that the 307 
mechanisms differ for postprandial glucose levels. More studies to understand the mechanisms for 308 
the increase in postprandial glucose levels during pregnancy are therefore important. It is, 309 
however, important to note that there are fewer known SNPs associated with 2hG than FG- 310 
explaining less of the variance in the trait - and thus we have less power to detect a relationship 311 
that might be there. Larger GWAS on 2hG could reveal more associated SNPs - generating a better 312 
GRS - and larger GWAS on pregnant women with OGTT could assist in demonstrating a 313 
significant genetic overlap. 314 
GRSBMI explained some of the variation in the glucose measurements during pregnancy, 315 
suggesting that genetically determined BMI has a significant effect on glucose related variables 316 
during pregnancy. This is consistent with the fact that BMI is a shared risk factor for both GDM 317 
and T2D32, 33. GRST2D explained a significant proportion of the variation in 2hG and PC1 scores. 318 
It should be noted that the associations involving GRSBMI and GRST2D were not significant after 319 
Bonferroni correction. Just as for GRS2hG, the polygenic GRS based on SNPs with p-value 320 
thresholds below genome-wide significance explained more variance than the GRS of just the 321 
known SNPs alone. As it is the 2hG value, and not FG, that is being explained by this risk score, 322 
this GRS might reflect beta cell function and/or insulin resistance during the OGTT. The 323 
involvement of GRST2D suggests some genetic overlap between GDM and T2D, which is in 324 
accordance with previous literature10, 11. One GWAS has investigated the relationship between 325 
genotypes and glucose measurements in pregnancy17 and found genome-wide significant influence 326 
of four known T2D genes on FG (Glucokinase Regulator (GCKR), Glucose-6-phosphatase 2 327 
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(G6PC2), Protein Phosphatase 1 Regulatory Subunit 3B (PPP1R3B) and Melatonin Receptor 1B 328 
(MTNR1B)). A GWAS of GDM, conducted in a Korean population, found that known T2D 329 
associated variants in the CDK5 Regulatory Subunit Associated Protein 1 Like 1 (CDKAL1) and 330 
MTNR1B gene regions were also associated with GDM16. However, although metabolic changes 331 
in pregnancy may look similar to those in the development of T2D, and although T2D and GDM 332 
share several genetic risk factors, the underlying mechanisms behind the diabetogenic 333 
development in pregnancy might be different.  334 
Our study is the first to examine the genetics of OGTT data at several time points during pregnancy. 335 
In our GWAS, we found three novel SNPs (rs116745876 (Mitogen-Activated Protein Kinase 336 
Kinase Kinase 1 (MAP3K1)), rs11682804 (Protein Kinase C Epsilon (PRKCE)), rs11112715 337 
(NUAK Family Kinase 1 (NUAK1)) which might potentially be related to glucose metabolism in 338 
pregnancy. However, our power calculations strongly suggest that these GWAS findings most 339 
likely represent type 1 errors, since the existence of SNPs with large effect size would be very 340 
atypical in the case of complex quantitative traits. We will therefore make our single marker test 341 
results available for future GWAS meta-analyses of these traits, and as a replication resource. The 342 
formation of large-scale consortia - as has been done for other glucose related traits and diseases - 343 
will be necessary to understand glucose metabolism during pregnancy and detect novel genetic 344 
loci for GDM. 345 
Our look-up of robustly associated glucose related variants in our study of pregnant mothers 346 
showed some nominally significant associations in the expected directions, although most of the 347 
SNPs were not significantly associated with the outcomes due to the low power of our study with 348 
respect to single-variant associations. When these variants were subsequently combined into GRS, 349 
power increased, and the combined effects of the SNPs show association with the glucose 350 
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measures in pregnancy. Finding the expected association between GRSFG and FG in early 351 
pregnancy confirmed that our sample had utility for using GRSs to test hypotheses about the 352 
genetic aetiology of glucose measures during pregnancy. We chose to present our main result 353 
without Bonferroni corrections, because the physiological traits the GRS are expected to reflect 354 
are highly correlated13. However, due to the metabolic changes during pregnancy, all analyses 355 
might be of physiological interest.  356 
Our previous findings indicated promising clinical relevance of the PC2 scores13, and the 357 
negligible associations between the GRSs and PC2 scores were therefore disappointing. This may 358 
partly be explained by the fact that the GRSs in our analyses were all based on single measurements, 359 
whereas the dynamic curve feature reflected in the PC2 (a delayed glucose peak combined with a 360 
prolonged period of high postprandial values) will not be covered by one single measurement. 361 
Similarly, whereas the AUC is a simple and good substitute for the PC1 scores13,  the dynamic, 362 
temporal information in the PC2 scores is not as easily replaced by simple measures. Calculating 363 
the timing of the glucose peak from five OGTT glucose measurements, without smoothing of the 364 
measurements and estimating continuous curves, could result in very crude measurements of the 365 
timing of the peak, and loss of information and precision. We therefore recommend that this curve 366 
characteristic is estimated by FDA. Validation of the physiological relevance of the PCs is 367 
important, but challenging, since few studies provide gold standard measurements of metabolic 368 
features in combination with FDA of OGTT. In non-pregnant populations, high correlations 369 
between HbA1c and FG and 2hG have been found34, 35. It may therefore be speculated that the 370 
information in average measurements like the HbA1c may partly overlap with the information in 371 
the PC1 scores. Furthermore, insulin resistance in the muscle can be shown as impaired glucose 372 
uptake after ingestion of a carbohydrate-rich meal and results in postprandial hyperglycemia36 and 373 
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that stress on the pancreatic β-cells may lead to impaired insulin secretion37. It is therefore 374 
reasonable to speculate that the PC2 might reflect aspects of insulin resistance or secretion. The 375 
genetic and environmental contribution to such mechanisms in pregnancy is not known, and these 376 
issues should be addressed in future studies, to gain more insight into the dynamics of glucose 377 
regulation.  378 
In this study we showed that known SNPs for FG appeared to explain similar percentages of 379 
variance in FG at two time points during pregnancy as in the non-pregnant population. GRS for 380 
BMI and T2D explained some of the variation in the maternal glucose measurements, including 381 
the glucose curve shape component interpreted as the general glucose level. Interestingly, SNPs 382 
weakly associated (p>5x10-8) with 2hG and T2D in GWAS data from the non-pregnant population 383 
seemed to explain more variation in the traits than the known genome-wide significant SNPs alone. 384 
These results highlight the importance of polygenic contributions to the glucose traits and suggest 385 
an overlap in the genetic aetiology of these traits in pregnant individuals and the non-pregnant 386 
population.   387 
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12. Figure legends:  505 
Figure 1: Flowchart for women included in the study.  485 women had 5 OGTT measurements at both 506 
GW 14-16 and 30-32. GW: gestational week; OGTT: oral glucose tolerance test.  507 
